Launching a revolutionary liquid biopsy kit in turbulent times
Liquid biopsies offer minimally invasive, safe and convenient means of diagnosing cancer, making them useful for regular screening and increasing the chance of catching cancer in the early stages. With earlier detection comes an a higher likely hood that a cancer patient can receive curative treatment. However, developing liquid biopsy kits can be challenging. Download this Leaflet to find out how Merck Millipore helped Elypta to overcome these challenges and establish a liquid biopsy test for glycosaminoglycans that has progressed to clinical trials. DOWNLOAD HERE
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
